MRI-informed biopsy recommendation reduces overdiagnosis in prostate cancer screening
1. In this randomized controlled trial of men aged 50 to 60, forgoing prostate biopsies in those with elevated PSA ...
Tag: prostate
The Scan by 2 Minute Medicine®: Slashing Seasonal Affective Disorder, Movember Movement, Syphilis Struggles, and Substance Use Disorders
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1 (pelvic bed radiotherapy alone). ...
#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer
1. Bone mineral density testing was associated with a significant decreased risk of developing major osteoporotic fractures among older men ...
#VisualAbstract: Prostate-Specific Membrane Antigen Positron Emission Tomography can be used to detect pelvic lymph nodes in prostate cancer
1. For the detection of pelvic nodal metastases in men with intermediate-to high-risk prostate cancer, using the 68Ga-PSMA-11 PET scan, the ...
#VisualAbstract: Ipatasertib plus abiraterone improves survival in PTEN-negative prostate cancer patients compared to abiraterone alone
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 ...
Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to abiraterone alone
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade ...
Image-guided salvage radiotherapy improves outcomes in patients with prostate cancer
1. 3-year event-free survival rates were significantly greater in the 18F-fluciclovine-PET group compared to conventional imaging. 2. Adverse reactions and ...
Radiolabeled Lutetium-177 offers higher PSA response versus cabazitaxel in metastatic castration-resistant prostate cancer
1. Radiolabeled Lutetium-177 offered greater PSA response versus current standard of care, cabazitaxel. 2. Fewer grade 3-4 adverse events occurred ...
Transdermal estrogen shows similar cardiovascular safety profile to traditional luteinizing hormone therapy in patients with prostate cancer
1. The use of long-term transdermal estrogen for castration therapy for prostate cancer showed no difference in cardiovascular events versus ...